Phase 1 trial: Tremelimumab, CTLA-4 directed mAb combined with radiotherapy for HCC

This Phase 1 study tests a preoperative protocol combining three fractions of focused radiotherapy with one dose of Tremelimumab followed by Durvalumab every four weeks, in patients with resectable or advanced hepatocellular carcinoma. Sponsored by Weill Medical College of Cornell University, the trial examines the safety and potential efficacy of this novel immunoradiotherapy approach.